RE:RE:RE:RE:RE:one article - new today Correction has been highlighted:
It looks like they are taking a more cautious approach in terms of promotion/getting the word out. You probably don't want to oversell potential on relatively limited trial data pre-BTD...jmo.
There needs to be an effective option that not only works, but one that is patient-friendly, doesn't break the bank & can be more easily accessible (i.e. more easily/efficiently manufactured). It's such a shame that in this modern era so many thousands of high-risk patients aren't even receiving the standard of care (SOC or BCG). Patients are being cut off from the SOC, receiving a lesser dose of the SOC, or not receiving the SOC at all due to the BCG shortages, which are expected to last for years. Someone at the FDA or higher needs to finally put patients before profits...we are all patients.
Our time will come...the FDA can't ignore the fact there are still so few FDA-approved options, all of which are expensive, treatment-intensive & have demonstrated fairly suboptimal efficacy.